Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

Cornell University, Итак, New York, United States
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 08/2006; 296(7):806-14. DOI: 10.1001/jama.296.7.806
Source: PubMed


The long-term adverse effects, expense, and difficulty of adherence to antiretroviral regimens have led to studies of simpler maintenance therapies. Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile.
To assess whether simplified maintenance therapy with atazanavir-ritonavir alone after virologic suppression increases the risk of virologic failure (2 consecutive human immunodeficiency virus type 1 [HIV-1] RNA measurements of > or =200 copies/mL).
Single-group, open-label, multicenter, 24-week pilot study of 36 HIV-infected adults with virologic suppression for 48 weeks or longer receiving their first protease inhibitor (PI)-based regimen. The study was conducted between September 1, 2004, and April 18, 2006, at 12 participating AIDS clinical trial units in the United States.
Participants switched PIs to atazanavir-ritonavir at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTIs) after 6 weeks.
Virologic failure within 24 weeks of discontinuing NRTIs. Other measures included HIV-1 drug resistance, plasma atazanavir concentrations, adverse events, CD4 cell counts, plasma lipid levels, and HIV-1 RNA levels in seminal plasma.
Thirty-six participants enrolled and 2 discontinued before simplification to atazanavir-ritonavir alone. Thirty-four patients were included in the analysis of the primary end point after 24 weeks: 1 withdrew voluntarily, and 33 continued the regimen. Virologic success (absence of failure) through 24 weeks of simplified therapy occurred in 91% (31 of 34 patients; lower 90% confidence interval limit = 85%). Three participants experienced virologic failure 12, 14, and 20 weeks after simplification, with plasma HIV-1 RNA levels of 4730, 1285, and 28 397 copies/mL, respectively. Resistance testing at failure did not identify PI resistance mutations. Plasma atazanavir concentrations at failure were low or below detection in 2 of 3 participants experiencing failure. There were no treatment discontinuations for adverse events after simplification; no significant changes in CD4 cell counts or plasma lipid levels; and no detectable HIV-1 RNA in seminal plasma from all 8 participants tested.
These preliminary data suggest that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for maintaining virologic suppression in carefully selected patients with HIV infection. These findings require confirmation in larger, randomized trials of this strategy. Identifier: NCT00084019.

Download full-text


Available from: Catherine Godfrey, Dec 12, 2013
  • Source
    • "Finally, boosted ATV has also been assessed as monotherapy. The ACTG 5201 study30 was a prospective pilot trial with 34 HIV adults with virological suppression for ≥48 weeks receiving their first PI regimen. All participants switched to boosted ATV at entry and discontinued the nucleoside analogue backbone after 6 weeks. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years. To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients. Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines. ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.
    Full-text · Article · Sep 2010 · HIV/AIDS - Research and Palliative Care
  • Source
    • "The efficacy of such treatments was limited by frequent adverse events and a significant interference of treatment in patients' lives (Moyle & Gazzard, 1999). In the present decade, strategies such as once-daily regimens have been developed to diminish the negative impact of treatment on quality of life and the appearance of less complex and toxic antiretroviral drugs has improved the management of HIV infection considerably (Negredo et al., 2004; Swindells et al., 2006). The effects of the benefits of these regimens on adherence have been uneven, however (Hammer et al., 2006), possibly because research has usually been carried out in already adherent patients with chronically suppressed viral loads (Negredo et al., 2004; Portsmouth et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to assess adherence of HIV-1-infected patients who started treatment in the pre-HAART era and to determine variables associated with better adherence, including relevant attitudes and beliefs. This is a cross-sectional study enrolling patients who had received antiretroviral therapy for >or=10 years. Adherence was evaluated through self-reporting and plasma drug concentrations. Treatment variables, attitudes and beliefs were collected during structured interviews. The results show that for 87 patients the median (interquartile range) time on therapy was 13 (10-19) years; 80 were on therapy at the time of analysis. Adherence was >or=95% in 54 patients (67.5%), 90-94% in 22 (27.5%) and <90% in 4 (5%). Drug concentrations were below the lower limit of detection in five patients. Younger age (p=0.014), female gender (p=0.005), current substance abuse (p=0.004) and hepatitis C virus co-infection (p<0.001) were related to lower adherence. Adherence did not differ in relation to different drug families or once- or twice-daily regimens. Patients with adherence <95% were more likely to have interrupted treatment without doctor's recommendation (p=0.009). Adherent patients exhibited a higher perception of risk of developing the illness and of benefits of therapy, higher self-efficacy and intention to adhere and were more influenced by events that motivate medication intake. To conclude, adherence was >90% in most patients on antiretroviral therapy for >or=10 years. Adherence was more related to beliefs about health and illness than to the characteristics of medication or level of knowledge about treatment. Care adherence interventions should include assessment of health beliefs.
    Full-text · Article · Aug 2008 · AIDS Care
  • Source
    • "If the decay rate of the latent reservoir in patients on standard HAART regimens has reached a maximum, then an intensified HAART regimen would have no benefit toward eradication of the latent reservoir – suggesting that other approaches would be necessary for eradication of the reservoir. In contrast, HAART simplification (reduction in the number of drugs) has been recently discussed as an option for reducing the burden of treatment on patients who have already achieved sustained virologic suppression [61]. Based on our findings, we expect that a simplified HAART regimen would maintain the decay rate of the latent reservoir as long as long virologic rebound is not observed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the setting of highly active antiretroviral therapy (HAART), plasma levels of human immunodeficiency type-1 (HIV-1) rapidly decay to below the limit of detection of standard clinical assays. However, reactivation of remaining latently infected memory CD4+ T cells is a source of continued virus production, forcing patients to remain on HAART despite clinically undetectable viral loads. Unfortunately, the latent reservoir decays slowly, with a half-life of up to 44 months, making it the major known obstacle to the eradication of HIV-1 infection. However, the mechanism underlying the long half-life of the latent reservoir is unknown. The most likely potential mechanisms are low-level viral replication and the intrinsic stability of latently infected cells. Here we use a mathematical model of T cell dynamics in the setting of HIV-1 infection to probe the decay characteristics of the latent reservoir upon initiation of HAART. We compare the behavior of this model to patient derived data in order to gain insight into the role of low-level viral replication in the setting of HAART. By comparing the behavior of our model to patient derived data, we find that the viral dynamics observed in patients on HAART could be consistent with low-level viral replication but that this replication would not significantly affect the decay rate of the latent reservoir. Rather than low-level replication, the intrinsic stability of latently infected cells and the rate at which they are reactivated primarily determine the observed reservoir decay rate according to the predictions of our model. The intrinsic stability of the latent reservoir has important implications for efforts to eradicate HIV-1 infection and suggests that intensified HAART would not accelerate the decay of the latent reservoir.
    Full-text · Article · Feb 2008 · BMC Infectious Diseases
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.